Genomic Health (GHDX) Issues Encouraging Update on Oncotype DX in Predicting Prostate Cancer
Tweet Send to a Friend
Genomic Health (NASDAQ: GHDX) announced results from two studies of the Oncotype DX prostate cancer test demonstrating its value in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
